Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026

China’s National Health Commission (NHC) has approved the “Standardized Pilot Program for Online Initial Consultations...

Company Drug

AstraZeneca Saphnelo Faces FDA Setback with Complete Response Letter

Fineline Cube Feb 5, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced it has received a Complete Response Letter (CRL) from the U.S....

Company

AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025

Fineline Cube Feb 5, 2026

AbbVie Inc. (NYSE: ABBV) reported fourth‑quarter revenue of USD 16.618 billion, up 9.5% year‑on‑year (YOY), bringing full‑year 2025...

Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026

Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its...

Company Deals

Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development

Fineline Cube Feb 5, 2026

Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for...

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Fineline Cube Feb 4, 2026

Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Fineline Cube Feb 4, 2026

Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026

Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026

Bio-Thera Solutions (SHA: 688177) announced a licensing agreement with Avalon Pharma, granting the Saudi Arabia‑headquartered...

Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026

Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for...

Company Drug

CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study

Fineline Cube Feb 4, 2026

China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has...

Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026

Akeso Biopharma (HKG: 9926) announced a partnership with Jumpcan Pharmaceutical (SHA: 600566) granting Jumpcan exclusive...

Company Drug

United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial

Fineline Cube Feb 4, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study

Fineline Cube Feb 4, 2026

Wuhan YZY Biopharma Co., Ltd (HKG: 2496) announced that the U.S. Food and Drug Administration...

Company

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales

Fineline Cube Feb 4, 2026

Amgen (NASDAQ: AMGN) reported fourth‑quarter 2025 revenue of USD 9.9 billion, up 9% year‑over‑year (YOY), bringing full‑year revenue...

Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026

Grand Pharmaceutical Group Limited (HKG: 0512) announced plans to acquire 100% equity in Hebei Grand...

Company

Novo Nordisk Sales Reach DKK 309 Billion on GLP‑1 and Obesity Surge

Fineline Cube Feb 4, 2026

Novo Nordisk (NYSE: NVO) reported 2025 global sales of DKK 309 billion (USD 48.9 billion), representing 10% year‑on‑year (YOY) growth...

Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026

Simcere Pharmaceutical Group Ltd (HKG: 2096) announced it has received a USD 40 million near‑term milestone payment from...

Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026

Medtronic Inc. (NYSE: MDT) announced it will exercise its option to acquire Israel-based medical device company...

Company Deals

TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline

Fineline Cube Feb 4, 2026

TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board...

Posts pagination

1 … 70 71 72 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.